Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-08

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a retrospective clinical study aimed at observing and evaluating the effectiveness and safety of checkpoint inhibitors in the treatment of patients with solid tumors in actual clinical applications. To explore predictors of efficacy patients with unresectable solid tumors receiving checkpoint inhibitors and develop and further validate predictive models.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

NCT04766515

Cancer

RECRUITING

Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases

NCT05129202

Non Small Cell Lung Cancer

COMPLETED

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer

NCT05059951

Non Small Cell Lung Cancer

RECRUITING

A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor

NCT07327294

Advanced Solid Tumors

NOT_YET_RECRUITING PHASE1/PHASE2

A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors

NCT05773937

Advanced Malignant Solid Tumors

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The clinical data of patients with unresectable solid tumors were collected retrospectively, who received two or more cycles of checkpoint inhibitor therapy. The progression-free survival (PFS), overall survival (OS) and related adverse reactions of the patients were followed up. To screen prognostic factors, develop predictive models and visualize them as nomograms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immunotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old and gender is not limited.
* Patients with unresectable solid tumors confirmed by pathology or histology.
* Patients received checkpoint inhibitor therapy for 2 cycles or more.

Exclusion Criteria

* Have a history of immunodeficiency, or suffer from other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation.
* Pre-existing thyroid dysfunction that cannot be maintained within the normal range even with medical treatment.
* Pregnant or breastfeeding women.
* Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders.
* The investigator judges that other conditions are not suitable for inclusion in the study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No